GLP-1 (Glucagon-like peptide-1) is a receptor agonist designed to help regulate hunger, slow digestion, and support steady, long-term weight managementall delivered through a convenient, physician-guided weekly injection
Furthermore, candidates for GLP-1 may include: Individuals with obesity who have a body mass index (BMI) of 30 or higher or who have a BMI of 27 or higher and also have at least one weight-related health condition, such as type 2 diabetes or high blood pressure
A TB-500 loading phase that changes halfway through
However, competent prescribing requires understanding appropriate patient selection, dose titration protocols, contraindication screening, side effect management, and monitoring requirements
It supports a more even skin tone and helps combat signs of aging by neutralizing free radicals and enhancing overall skin clarity
"FDA's determination was based on a thorough review of Novo Nordisk's stable and growing supply of these important FDA-approved medicines